This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
PEG-PAL End of Phase 2 Meeting Completed, Phase 3 to Begin Next Quarter
Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
Financial Highlights ($ in millions, except per share data, unaudited)
Total BioMarin Revenue
Total Net Product Revenue
Naglayzme Net Product Revenue
Aldurazyme BioMarin Net Product Revenue
Kuvan Net Product Revenue
Firdapse Net Product Revenue
GAAP Net Loss
GAAP Net Loss per Share (basic and diluted)
Non-GAAP Adjusted EBITDA Income (Loss)
Cash, cash equivalents and short and long-term investments*
* The cash balance at the end of 2012 includes net proceeds of $235.5 million from the public offering in June 2012.
SAN RAFAEL, Calif., Feb. 21, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced financial results for the fourth quarter and full year 2012. GAAP net loss was $53.0 million ($0.43 per share) for the fourth quarter of 2012, compared to GAAP net loss of $26.7 million ($0.23 per share) for the fourth quarter of 2011. Non-GAAP adjusted EBITDA was a loss of $15.5 million for the fourth quarter of 2012, compared to non-GAAP adjusted EBITDA loss of $3.0 million for the fourth quarter of 2011. The increased GAAP net loss and the reduced non-GAAP adjusted EBITDA for the fourth quarter of 2012 compared to the fourth quarter of 2011 was primarily due to increased net product revenue offset by a larger increase in research and development expenses.